MedTrace Logo

Trial Evaluating Hypo-fractionated Accelerated Versus Conventional Fractionated Adjuvant RT in Head & Neck Malignancies

NCT07573956 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 369

Last updated 2026-05-07

No results posted yet for this study

Summary

Hypo-fractionated radiotherapy reduces the OTT (overall treatment time) which may in turn reduce rapid accelerated repopulation of clonogenic cells during waiting period after surgery. If this holds true, there is a potential to achieve better loco-regional control in with PORT for HNSCC. There is a strong radiobiological and economic rationale for delivery hypo-fractionated radiotherapy in HNSCC. The HYPCON III trial will be aimed to reduce the number of fractions by 50% (30 fr to 15 fr)

Conditions

  • Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)

Interventions

RADIATION

Standard conventionally fractionated PORT

60Gy in 30 fractions over 6 weeks (5 fractions per week)

RADIATION

hypo-fractionated PORT

4Gy in 15 fractions over 3 weeks (5 fractions per week)

Sponsors & Collaborators

  • Indian Council of Medical Research

    collaborator OTHER_GOV

  • All India Institute of Medical Sciences

    lead OTHER

Principal Investigators

  • Dr. Aman Sharma · National cancer Institute, AIIMS, Jhajjar

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-10
Primary Completion
2028-06-30
Completion
2028-12-30

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07573956 on ClinicalTrials.gov